Macquarie Group
AST

Macquarie Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Macquarie Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,800
Closed -$9K – 2571
2017
Q4 		$9K Buy
+3,800
New +$9.62K ﹤0.01% 2296

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Macquarie Group's AST Position: Q1 2018 in Review

Macquarie Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2018, closing a stake of 3,800 shares — an estimated $9K sold.

Macquarie Group first reported a position in AST in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 72 funds tracked by Wall St. Rank hold AST as of Q1 2018.

  • Macquarie Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 3,800 Asterias Biotherapeutics Inc. Series A shares in Q1 2018, an estimated $9K.
  • Macquarie Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Asterias Biotherapeutics Inc. Series A position peaked at $9K in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.